was excellent with a mean of 96.1% (range 95.2%-100%) of pills consumed over the 12-week treatment.
.
Of the 131 886 Lifelines participants (age 45 AE 13 years, 40% males), 47% were nonsmokers, 33% were former smokers and 20%
were current smokers. Of the current smokers, 28% smoked <6 cigarettes per day, 55% smoked 6-20 cigarettes per day and 18% smoked > 20 cigarettes per day. Hemoglobin levels were higher in current smokers (14.3 AE 1.2 g/dL) compared with nonsmokers (14.0 AE 1.3 g/dL, P < .001). Similarly, MCV levels were higher in current smokers (91.4 AE 4.3 fL) compared with nonsmokers (89.2 AE 4.0 fL, P < .001, Figure 1A ). Macrocytosis was present in 494 (1.9%) of current smokers compared with 166 (0.3%) of nonsmokers (P < .001, Figure 1B ).
In univariable linear regression analysis, current smoking, compared with nonsmoking, was positively associated with MCV (β = 0.24, P < .001). In multivariable regression analysis, performed in the whole cohort, current smoking compared with nonsmoking, remained positively associated with MCV (β = 0.23, P < .001), independent of adjustment for age, sex, estimated glomerular filtration rate (eGFR), body mass index (BMI), and alcohol use. Multivariable regression analysis was also performed in a subgroup of participants from whom also gamma-
Association of smoking and 24-hour urinary cotinine excretion levels with mean corpuscular volume and macrocytosis. A, The association between smoking status and MCV in the lifelines cohort. Reported P-values are shown in respect to reference category of nonsmokers. B, The prevalence of macrocytosis for each smoking status in the lifelines cohort. Reported P-values are shown in respect to reference category of nonsmokers. C, The association between smoking status and MCV in the PREVEND study. Reported P-values are shown in respect to reference category of nonsmokers. D, The association between 24-hour urinary cotinine excretion levels and MCV by means of restricted cubic splines. Three knots have been specified at the 10th, 50th, and 90th of 24-hour urinary cotinine percentiles. The 95% CIs are indicated by the shaded areas. Twenty-four urinary cotinine levels have been natural log transformed. Abbreviations: MCV, mean corpuscular volume; PREVEND, prevention of renal and vascular end-stage disease. *P < .05 **P < .01 ***P < .001 glutamyltransferase (GGT), alanine aminotransferase (ALAT), free thyroxine (FT4), and high-sensitivity C-reactive protein (hs-CRP) were available (n = 36 109) with the same result (β = 0.23, P < .001).
Similarly, in logistic regression, smoking was a strong determinant of macrocytosis (OR 6.25, 95% CI 5.2-7.51; P < .001 in the total cohort, OR 6.00, 95% CI 4.12-8.73; P < .001 in the subgroup of n = 36 109), independent of adjustment for potential confounders.
Hereafter, we divided current smoking into categories of ciga- Of the 6808 subjects (age 53 AE 12 years, 50% males) in the PRE-VEND study, 29% were nonsmokers, 43% were former smokers, and 28% were current smokers. Of the latter, 16% smoked <6 cigarettes per day, 70% smoked 6-20 cigarettes per day, and 14% smoked >20 cigarettes per day. Hemoglobin levels were higher in current smokers (13.9 AE 1.2 g/dL) compared with nonsmokers (13.6 AE 1.3 g/dL, P < .001). Similarly, MCV levels were higher in current smokers (92.3 AE 4.7 fL) compared with nonsmokers (89.2 AE 4.3 fL, P < .001, Figure 1C ). Macrocytosis was present in 73 (4%) of current smokers compared with 8 (0.4%) of nonsmokers (P < .001).
In univariable linear regression analysis, current smoking, compared with nonsmoking, was positively associated with MCV (β = 0.30, P < .001). In multivariable analysis, current smoking, compared with nonsmoking, remained positively associated with MCV (β = 0.24, P < .001), independent of adjustment for age, sex, eGFR, BMI, hs-CRP, alcohol use, GGT, ALAT, FT4, vitamin B 12 , and folic acid.
Similarly, in logistic regression, smoking was a strong determinant of macrocytosis (OR, 8.54, 95% CI 2.57-28.37; P < .001), independent of adjustment for potential confounders.
Hereafter, we divided current smoking into categories of cigarettes smoked per day. In multivariate analysis, smoking <6 cigarettes (β = 0.03, P = .06), was not associated with MCV, whereas smoking 6-20 cigarettes (β = 0.24, P < .001), and smoking >20 cigarettes per day (β = 0.13, P < .001) remained, compared with nonsmoking, associated with MCV, independent of adjustment for potential confounders.
As sensitivity analysis, we repeated in the PREVEND study the analysis with 24-hour urinary cotinine excretion levels as objective reflection of smoking. Twenty-four hour urinary cotinine excretion was strongly correlated with current smoking (β = 0.82, P < .001). Similar to the primary analysis, we identified a strong positive association between 24-hour urinary cotinine excretion and MCV (β = 0.26, P < .001, Figure 1D ). The association remained independent of adjustment for potential confounders (β = 0.23, P < .001).
In this study, we have shown that smoking, assessed both by means of a self-administered questionnaire and by 24-hour urinary cotinine excretion levels, was strongly positively associated with MCV.
Importantly, this association was independent of known causes of macrocytosis, including alcohol use. A few years ago, McNamee et al. 5 and O'Reilly et al. 6 reinvestigated the association between smoking as unrecognized cause of macrocytosis and showed that cigarette smoking was a significant risk factor for macrocytosis, independent of other known causes. Unfortunately, at present cigarette smoking is still not mentioned in textbooks and major guidelines, and clinicians are generally unaware of this association. The major drawback of the previously performed studies was that smoking status was assessed by means of a self-administered questionnaire, which might still be regarded as a subjective measurement of smoking status. In this study, we underline the importance of this association, and we are the first to utilize an objective measurement that is, urinary cotinine excretion levels, for the current association. The latter combined with the large patient populations can be regarded also as the major strength of this study. Due to the observational design of this study, we cannot discern potential mechanisms for the strong association between smoking and MCV. Finally, despite the extensive number of factors for which we adjust, residual confounding can still not be excluded.
In conclusion, smoking is an important determinant of MCV levels and macrocytosis, independent of prominent causes such as alcohol intake, liver disease, vitamin B 12 , and folic acid deficiency. Smoking should be included in current guidelines regarding known causes of an elevated MCV, and the current study might draw more attention to the mechanism by which smoking causes macrocytosis independent of alcohol intake.
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